Two decades of new drug development for central nervous system disorders

Nature Reviews Drug Discovery

Volumn 14, Issue 12, 2015, Pages 815-816

  Kesselheim, Aaron S ^a   Hwang, Thomas J ^b,c   Franklin, Jessica M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Bain Capital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; NEW DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; FUNDING; HUMAN; MEDICAL RESEARCH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; STRATEGIC PLANNING; TREATMENT WITHDRAWAL; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DEVELOPMENT; PROCEDURES; TRENDS;

CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; PHARMACOLOGY, CLINICAL;

EID: 84948712481     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4793     Document Type: Short Survey

References (0)